Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

More than 36,000 people join Cancer Research UK's Voice for Radiotherapy campaign

More than 36,000 people have joined Cancer Research UK's Voice for Radiotherapy campaign to call on the government to improve radiotherapy services in England.

5 Nov 2011

Vertex announces 16 grant recipients of Hep-C Circle of Care program

Vertex Pharmaceuticals Incorporated today announced that it has awarded 16 grants totaling approximately $1.5 million to a variety of academic, patient and community groups as part of the Vertex Hep-C Circle of Care program, a pilot competitive grants program designed to foster innovative approaches to patient care and support people living with chronic hepatitis C.

5 Nov 2011

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, together with its international commercialization partners, today announced that enrollment has been initiated and the first patient has been randomized in a Phase 2b clinical trial called TRAVERSE.

4 Nov 2011

Galectin Therapeutics forms Liver Fibrosis Clinical Trials Advisory Board

Galectin Therapeutics Inc., the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin receptors, today announced the formation of its Liver Fibrosis Clinical Trials Advisory Board comprised of key opinion leaders from Emory Hospital and School of Medicine, Massachusetts General Hospital and Harvard School of Medicine, University of Michigan Hospital and School of Medicine, Mount Sinai Hospital and School of Medicine, and University of Wisconsin Hospital and School of Medicine.

3 Nov 2011

Solid organ transplant may increase risk of cancer

Patients who have received a solid organ transplant, such as kidney, liver, heart or lung, have an overall cancer risk that is double that of the general population, with an increased risk for many different types of malignancies, according to a study in the November 2 issue of JAMA.

2 Nov 2011

Potential transmission of HBV, HCV and HIV infections in nail salons and barbershops

The risk of hepatitis transmission through non-single use instruments -- such as nail files, nail brushes, finger bowls, foot basins, buffers, razors, clippers, and scissors -- during nail salon and barbershop visits cannot be excluded, according to the results of a new report unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

NHS must plan to deal with predicted 45% leap in new cancer cases

The NHS must start planning now to deal with a predicted leap of 45 per cent in the number of new cancer cases in the UK over the next two decades, Cancer Research UK warns today (Friday).

28 Oct 2011

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCISE that will evaluate the potential for treatment with INCIVEK (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the 'CC' variation near the IL28B gene.

24 Oct 2011

Common risk factors for hepatocellular cancer

Among known risk factors for hepatocellular cancer, smoking, obesity, and heavy alcohol consumption, along with chronic hepatitis B and C infection, contribute to a large share of the disease burden in Europe, according to a cohort study published online October 21 in the Journal of the National Cancer Institute.

22 Oct 2011

Two Philadelphia scientists to receive John Scott Award

Two internationally recognized scientists with strong Philadelphia ties are to receive the John Scott Award this year.

21 Oct 2011

Advances in yttrium-90 radioembolization for liver cancer

Finding innovative, minimally invasive ways to treat liver cancer-and being able to tailor that treatment individually to patients-are hallmarks of interventional radiologists. Advances in yttrium-90 (Y-90) radioembolization for liver cancer, a leading cause of cancer deaths worldwide, are reported in studies in the October Journal of Vascular and Interventional Radiology.

20 Oct 2011

Acute HCV screening strategy for HIV-infected individuals

Researchers at The Miriam Hospital demonstrated a practical strategy for regularly screening HIV-infected patients for acute hepatitis C virus infection (HCV), a "silent epidemic" that is rising undetected in this population and can lead to serious health complications.

19 Oct 2011

Nanofiber borate glass material may help heal diabetic wounds

Diabetics who suffer from hard-to-heal open wounds may soon have help in the form of a cottony glass material developed at Missouri University of Science and Technology.

15 Oct 2011

EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended 4SC's anti-cancer compound resminostat for designation as orphan medicinal product for the treatment of Hodgkin's Lymphoma (HL), a cancer of the lymphatic system.

13 Oct 2011

GOP candidates prepare for debate; Romney appears to be everyone's target

The Republican presidential hopefuls will face off Tuesday evening in New Hampshire. Even before the event begins, candidates are staking their ground. Texas Gov. Rick Perry went on the offensive, releasing a web video attacking former Mass. Gov. Mitt Romney's health care positions. Meanwhile, the debate will be very important to Herman Cain, who has been climbing in the polls, and Michele Bachmann, who has fallen precipitously.

12 Oct 2011

Isis designates ISIS-AATRx candidate in collaboration with GSK

Isis Pharmaceuticals, Inc. announced today that it has designated the second development candidate, ISIS-AATRx, in its collaboration with GlaxoSmithKline

12 Oct 2011

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

Scripps Research receives NIH grant to determine how HCV induces liver cancer

The Scripps Research Institute has been awarded a $2.2 million grant by the National Institutes of Health (NIH) to determine how the hepatitis C virus (HCV) induces liver cancer.

11 Oct 2011

Positive results from Biotron's BIT225 Phase 2a trial on HCV

Australian drug development company Biotron Limited has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients.

11 Oct 2011

VGX International, Inovio partner to co-develop SynCon vaccines for hepatitis B and C infections

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc., to co-develop Inovio's SynCon therapeutic vaccines for hepatitis B and C infections.

10 Oct 2011